Royalty Pharma price to sales ratio RPRX

Market value divided by revenue over the last twelve months, since 2021.

Today, Oct 23, 2026: 14.5×
6-year median: 9.8×
Against its 6-year history: 99th; percentile: 0 is its lowest day, 100 its highest
6-year range: 6.5× to 14.5×
Peer median: 6.7×

Royalty Pharma's price to sales ratio is 14.5× as of Oct 23, 2026.

That is above its 6-year median of 9.8×, higher than on 99% of days in the last 6 years.

Over that time it ranged from 6.5× in Dec 2024 to 14.5× in Sep 2026.

The median for 10 healthcare stocks of a similar size is 6.7×.

Price to sales ratio over time

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2026 so far	14.5×	9.5×	14.5×
2025	9.6×	6.7×	9.8×
2024	6.6×	6.5×	7.9×
2023	7.2×	6.7×	10.6×
2022	10.7×	10.1×	11.9×
2021	10.6×	9.6×	13.4×

Against its peers

Companies in Healthcare nearest Royalty Pharma's size, closest first, today.

Company	Price to sales ratio
RPRXRoyalty Pharma	14.5×
RMDResMed	6.5×
BIIBBiogen	3.7×
CNCCentene	0.2×
ZTSZoetis	3.5×
MTDMettler-Toledo International	8.1×
ILMNIllumina	9.1×
GEHCGE HealthCare Technologies	1.5×
ONCBeOne Medicines	7.0×
IDXXIDEXX Laboratories	9.7×
WATWaters	9.6×
Peer median	6.7×

What the price to sales ratio tells you

Market value divided by revenue over the last twelve months. Useful for companies with little or no profit yet, since sales are harder to make negative than earnings.

Ignores margins entirely. A software company at 10× sales with 30% margins can be cheaper than a grocer at 1× sales with 2% margins.

More on Royalty Pharma

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.